Back to Hematology
Hematologyv2016Evidence-Based

WHO Diagnostic Criteria for Systemic Mastocytosis (2016)

World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.

Clinical Input Parameters

ng/mL
Range: 0 — 200 ng/mL
Clinical Assessment
Awaiting Parameters
diagnosis status
—categorical
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Diagnosis requires: (1 major criterion + 1 minor criterion) OR (3 minor criteria). Major criterion: multifocal mast cell infiltrates ≥15 cells. Minor criteria: (1) atypical morphology ≥25%, (2) KIT mutations, (3) aberrant CD expression, (4) serum tryptase >20 ng/mL.

Clinical Pearls & Practice Notes

  • Serum tryptase >20 ng/mL criterion only valid in absence of associated myeloid neoplasm
  • Most common mutation is KIT D816V found in >95% of adult systemic mastocytosis cases
  • Bone marrow biopsy with immunohistochemistry/flow cytometry typically required for definitive diagnosis
  • Hereditary alpha-tryptasemia can cause elevated tryptase and should be considered in differential
  • Distinguish from cutaneous mastocytosis which lacks systemic involvement
  • May be associated with other hematologic malignancies in aggressive forms

Evidence & Literature Citations

  1. Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5(11):e646. doi: 10.1097/HS9.0000000000000646
  2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi: 10.1182/blood-2016-03-643544
  3. Valent P, Alin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893
  4. Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(8):1306-1325. doi: 10.1002/ajh.26962

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.